NTHI
Neonc Technologies Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Neonc Technologies Holdings, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
0.00%
NTHI weight · VTI
Neonc Technologies has 10 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceIn December 2022, the Company signed a Letter of Intent ("LOI") with an investment advisory firm AFH Holdings and Advisory, LLC ("AFH") to create a newly formed corporation called NeOnc Technologies Holding Company, Inc. ("NTHI") to facilitate future fundraising transactions.
NTHI 10-Kaccession 0001829126-26-002860
SentenceIn February 2025, our Executive Chairman, Amir F. Heshmatpour, advanced the Company approximately $300,000.
NTHI 10-Kaccession 0001829126-26-002860
SentenceThe institutions that participated in the trial were Cleveland Clinic, University of Washington/Seattle, University of Wisconsin, and the University of Southern California.
NTHI 10-Kaccession 0001829126-26-002860
SentenceIt was sponsored by NeOnc Technologies, Inc. (Los Angeles, CA) with ClinDatrix, Inc. (Irvine, CA), as the Clinical Data Management CRO (Contract Research Organization).
NTHI 10-Kaccession 0001829126-26-002860
SentenceNTHI acquired exclusive rights to a patented 3D bioprinting platform developed at McMaster University (U.S. Patent No. 11,788,057 B2).
NTHI 10-Kaccession 0001829126-26-002860
SentenceIn August and September 2025, the Company was awarded two grants totaling approximately $1,400,000 in gross proceeds from the National Institutes of Health (NIH).
NTHI 10-Kaccession 0001829126-26-002860
SentenceIn June 2025, the Company (through its recently formed subsidiary – Nuromena Holdings Ltd. "NuroMena") entered into a letter of intent to form an investment and joint venture agreement with a Middle-East investor ("Investor"), Quazar Investments.
NTHI 10-Kaccession 0001829126-26-002860
SentenceThe institutions that participated in the trial were Cleveland Clinic, University of Washington/Seattle, University of Wisconsin, and the University of Southern California.
NTHI 10-Kaccession 0001829126-26-002860
SentenceThe institutions that participated in the trial were Cleveland Clinic, University of Washington/Seattle, University of Wisconsin, and the University of Southern California.
NTHI 10-Kaccession 0001829126-26-002860
SentenceOur license agreement with USC, under which we license all of our current patent rights and a significant portion of our technology for our product candidates, imposes royalty and other financial obligations on us and other substantial performance obligations.
NTHI 10-Kaccession 0001829126-26-002860
SentenceOn July 1, 2022, NeOnc Technologies, Inc. and Fox Infused, LLC, a Delaware limited liability company ("Fox Infused"), entered into an Intellectual Property License and Supply Agreement effective July 1, 2022 (the "Agreement") whereby NeOnc agreed to supply certain products to Fox Infused and license certain of our patents.
NTHI 10-Kaccession 0001829126-26-002860
SentenceInstead, the Company and OEP negotiated a settlement that resulted in the termination of the collaboration agreement and all of OEP's license rights and resolved all disputes between the parties.
NTHI 10-Kaccession 0001829126-26-002860
Neonc Technologies Holdings, Inc.
3.28
Largest filed tie
—
Expected move
No implied move.
+30.80%
shares held · 10 largest managers